HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $80 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Celldex Therapeutics (NASDAQ:CLDX) and maintained a price target of $80.
July 16, 2024 | 5:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Celldex Therapeutics and maintained a price target of $80, indicating strong confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a high price target by a reputable analyst firm like HC Wainwright & Co. is a strong positive signal for investors. It suggests confidence in the company's future performance and potential for stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100